Jeffries Oliver-Li's practice focuses on corporate and securities law matters. He represents companies in public offerings, venture capital financings and mergers and acquisitions. Mr. Oliver-Li also advises companies with respect to securities law compliance and disclosures and general corporate matters.

Mr. Oliver-Li's public company clients include Casa Systems, Catabasis Pharmaceuticals, Editas Medicine, EverQuote and PerkinElmer.

Mr. Oliver-Li's transactional practice has included representation of:

  • Casella Waste Systems, Inc. in its tender offer for and redemption of $195 million of senior subordinated notes;
  • Catabasis Pharmaceuticals, Inc. in its $69 million initial public offering;
  • Constellation Pharmaceuticals, Inc. in its $55 million mezzanine financing;
  • CoreStreet, Ltd. in its acquisition by ActivIdentity Corporation for $19 million;
  • Editas Medicine, Inc. in its $109 million initial public offering;
  • Netezza Corporation in its acquisition by IBM for $1.9 billion;
  • Sonus Networks, Inc. in its acquisition of Network Equipment Technologies, Inc. for $42 million;
  • Tangoe, Inc. in its $100 million initial public offering and its $170 million follow-on offering; and
  • Tetraphase Pharmaceuticals, Inc. in its $80 million initial public offering.

While in law school, Mr. Oliver-Li held a summer associate position with WilmerHale, working primarily in corporate law and litigation.

Insights & News


  • Education

    • JD, Harvard Law School, 2006

      cum laude Harvard Journal of Law & Technology
    • AB, History of Art & Architecture, Harvard College, 2003

      summa cum laude Phi Beta Kappa, Thomas Temple Hoopes Prize
  • Admissions

    • Massachusetts

    • Colorado



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.